Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-19

Clinical Trial Update: Activity of Sorafenib in Salivary Gland Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on sorafenib in salivary gland cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Salivary Gland Cancer | Phase 2 | Status: COMPLETED